All News

January 12, 2023

Antibody “fingerprinting” method potential advance to slow spread of dengue

Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.

By Bill Snyder
Alexander Bick, MD, PhD, and colleagues are studying inflammation at the single-cell level in the rare disease RUNX1-FPD.
January 12, 2023

Chan Zuckerberg Initiative grant supports single-cell study of rare inherited disease

A multidisciplinary team led by Vanderbilt University Medical Center investigator Alexander Bick, MD, PhD, has been awarded a $2 million, four-year grant to study inflammation at the single-cell level in the rare disease RUNX1-FPD.

By Leigh MacMillan
January 12, 2023

Study may lead to new diabetes, heart disease treatments

Vanderbilt research found that deletion of an autophagy-participating factor named PIK3C3 from the fat cells of mice led to compromised body temperature control, abnormal blood lipid levels, fatty liver and diabetes.

By Bill Snyder
January 12, 2023

Sharp named Southern Surgical Association president

Vanderbilt’s Kenneth Sharp, MD, has been named president of the Southern Surgical Association (SSA).

By Jill Clendening
January 12, 2023

Roden honored for his leadership in precision medicine

Vanderbilt’s Dan Roden, MD, will receive the PMWC 2023 Pioneer Award Jan. 27 during this year’s Precision Medicine World Conference.

By Bill Snyder
January 10, 2023

Anti-nausea drug response in children

Genetic variation in a metabolic enzyme was not associated with response to the anti-nausea drug odansetron in children, Vanderbilt researchers report.

By Leigh MacMillan
January 9, 2023

Novel lung cancer biomarker

Autoantibodies against the p53 tumor suppressor protein may be a novel biomarker for identifying people, especially African Americans, at high risk for lung cancer.
By Leigh MacMillan
January 9, 2023

Nashville Biosciences and Illumina announce sequencing agreement with Amgen

Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center, and Illumina Inc., a global leader in DNA sequencing and array-based technologies, today announced an agreement with Amgen, a global biopharmaceutical company, to whole-genome sequence approximately 35,000 DNA samples.
By VUMC News and Communications
January 6, 2023

Early effects of Huntington disease

Impairments in brain executive function happen earlier than motor symptoms in people with the gene mutation that causes Huntington disease, suggesting younger ages and cognitive symptoms be considered for any future clinical trials.
By Kelsey Pinckard
January 6, 2023

MicroRNAs linked to lipid damage

VUMC researchers have linked microRNAs with systemic lipid peroxidation, a discovery that could point to new therapeutic targets for a variety of diseases.
By Sarah E. Glass
January 5, 2023

VUMC researchers upend dogma about vasopressin production

Vanderbilt investigators have discovered that vasopressin, which has long been thought to be produced only in the brain, is also produced in the kidney.
By Leigh MacMillan
January 5, 2023

Infectious disease expert Edwards ends storied career

Vanderbilt's Kathryn Edwards, MD, internationally recognized for her countless contributions to vaccine evaluation and implementation, public health advocacy, and the mentorship and training of new generations of experts in infectious disease over the past four decades, retired on Dec. 31, 2022.
By Nancy Humphrey
January 5, 2023

Three elected to the American Pediatric Society

Three physicians in the Vanderbilt Department of Pediatrics have been elected to the American Pediatric Society.
By Christina Echegaray
1 … 65 66 67 68 69 … 98